Cabozantinib Improves Survival in Advanced Hepatocellular Cancer

Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma, according to research in the New England Journal of Medicine. Researchers randomized 707 patients with advanced hepatocellular carcinoma in a 2-to-1 ratio to receive cabozantinib or matching placebo and found significantly longer overall survival with cabozantinib than placebo at the second planned interim analysis. The researchers found that the median overall survival was 10.2 and 8.0 months with cabozantinib and placebo, respectively.

Mon, 09 Jul 2018 BREAKING NEWS
New Rules May Constrain Docs’ Ability to Treat Chronic Pain

New laws and regulations designed to limit the use of prescription narcotics may further constrain doctors’ ability to treat patients, according to an article in Medical Economics. Physicians express concern that they cannot exercise their clinical judgement about the appropriate therapy for specific patients, and that CMS rules and CDC guidelines conflict.

Fri, 06 Jul 2018 BREAKING NEWS
Enzalutamide Improves Outcomes for Aggressive Prostate Cancer

(HealthDay News) Enzalutamide treatment can significantly lower risk of metastasis or death in men with rapidly advancing, castration-resistant prostate cancer, according to a phase 3 study in the New England Journal of Medicine. “Among men with … with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo,” conclude the authors.

Twitter Posts Reveal Use of JUUL Vaporizer by Minors at School

(HealthDay News) Data from social media capture early public experiences with the JUUL vaporizer, a nicotine delivery device that is the size and shape of a thumb drive, research in Drug and Alcohol Dependence finds. “Findings suggest Twitter users are bonding around, and inquiring about, JUUL on social media,” the authors write.

Mon, 02 Jul 2018 FAMILY PRACTICE
Initial Outcomes No Worse for Surgical ICU Patients With CA

Surgical patients who are admitted to the intensive care unit (ICU) and have cancer do not have worse initial outcomes than those without cancer, according to research in JAMA Surgery. “Cancer is a common diagnosis among surgical ICU patients and this study suggests that initial outcomes compare favorably with those of ICU patients with other conditions,” the authors write. “Consideration that a diagnosis of cancer should not preclude admission to the ICU in patients with surgical disease is suggested.”

Fri, 29 Jun 2018 BREAKING NEWS
ADA: Closed-Loop Insulin Improves Glycemic Control

Use of an automated, closed-loop insulin delivery system results in significantly better glycemic control than conventional subcutaneous insulin therapy among patients with type 2 diabetes receiving noncritical care, according to a study published in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held in Orlando, Florida.

Fri, 29 Jun 2018 BREAKING NEWS